Invokana (canagliflozin) / J&J, Daiichi Sankyo, Tanabe Pharma, Mundipharma - LARVOL DELTA

Assessment of monotherapy and combination therapy with canagliflozin, metformin, and fenugreek seed extract in experimental diabetic osteopathy. (PubMed, 3 Biotech) - "Histological findings were consistent with the micro-computed tomography (micro-CT) observations. Overall, canagliflozin-based combination treatments were associated with improved metabolic control and attenuation of femoral trabecular deterioration in this experimental model, supporting further investigation of their skeletal effects and underlying mechanisms."

Journal • Monotherapy • Diabetes • Metabolic Disorders

SGLT-2 Inhibitors Are Associated With Reduced Hepatic Decompensation and Mortality in Patients With Cirrhosis and Type 2 Diabetes: A Propensity-Matched Real-World Analysis (ACG 2026) - "Adults with cirrhosis and T2DM receiving dapagliflozin, empagliflozin, or canagliflozin were compared with matched controls receiving furosemide and spironolactone without SGLT2 inhibitor exposure. : After PSM, SGLT2 inhibitor use was associated with a significantly lower risk of the composite hepatic decompensation outcome at 3 years (2.3% vs 3.6%; HR 0.58, 95% CI 0.49-0.69; p< 0.001). Individual analyses demonstrated lower risks of SBP (HR 0.43, 95% CI 0.31-0.58; p< 0.001) and peritoneal drainage/paracentesis-related procedures (HR 0.63, 95% CI 0.52-0.76; p< 0.001). Independent assessment of variceal bleeding was limited by low event counts."

Clinical • Real-world • Real-world evidence • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Fibrosis • Hepatocellular Cancer • Hepatology • Immunology • Liver Failure • Metabolic Disorders • Nephrology • Renal Disease • Solid Tumor • Type 2 Diabetes Mellitus

Comparative Cardiorenal Efficacy and Safety of Finerenone, SGLT2 Inhibitors, Semaglutide and Their Combination in Diabetic Kidney Disease. (PubMed, Diabetes Obes Metab) - "SGLT2i showed the broadest cardiorenal benefits, while finerenone and semaglutide provided additional protection across selected outcomes. Finerenone increased hyperkalaemia and treatment discontinuation. The efficacy of finerenone-SGLT2i combination therapy requires further investigation."

Journal • Cardiovascular • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

GLP-1 Receptor Agonists Versus SGLT-2 Inhibitors in Fibrotic MASLD With Obesity and Type 2 Diabetes: A Propensity-Matched Real-World Analysis of Hepatic and Mortality Outcomes (ACG 2026) - "Cohort 1 received GLP-1RAs (semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, lixisenatide); Cohort 2 received SGLT-2is (empagliflozin, dapagliflozin, canagliflozin, ertugliflozin)... Post-matching cohorts were balanced (47.4% female, ~69% White). New cirrhosis did not differ significantly (0.11% vs. 0.15%; RR 0.74, 95% CI 0.48â1.13; p=0.16)."

Clinical • Real-world • Real-world evidence • Diabetes • Fibrosis • Genetic Disorders • Hepatology • Immunology • Liver Cirrhosis • Liver Failure • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Pancreatitis • Type 2 Diabetes Mellitus

Effects of SGLT2 Inhibitors in Rodent Models of Diabetic Nephropathy. (PubMed, Handb Exp Pharmacol) - "Clinical outcome studies have established sodium glucose transporter 2 (SGLT2) inhibitors such as canagliflozin, dapagliflozin, and empagliflozin as nephroprotective agents in diabetic patients. Improvements in female animals tended to be weaker or absent for parameters that were consistently improved in male rodents. Whether this is a peculiarity of the rodent studies or a similar situation exists in diabetic patients remains to be tested."

Journal • Preclinical • Diabetes • Diabetic Nephropathy • Fibrosis • Glomerulonephritis • Immunology • Metabolic Disorders • Nephrology • Renal Disease • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Differential uptake of SGLT2 inhibitors in England following heart failure guideline expansion: a controlled interrupted time series analysis. (PubMed, BMJ Open) - "SGLT2 inhibitor uptake in English primary care has been highly heterogeneous. The marked acceleration in dapagliflozin prescribing from July 2023, against stable background trends for canagliflozin, is temporally consistent with expanded heart failure guideline recommendations. However, several important limitations preclude definitive causal attribution. First, because this study analysed aggregate prescribing data without patient-level indications, we cannot directly attribute observed changes to heart failure rather than to diabetes, chronic kidney disease or other factors. Second, the substantial concurrent reduction in dapagliflozin's NIC (from £1.38 to £0.35 per DDD) represents a competing explanation; exploratory adjustment for NIC attenuated the dapagliflozin estimate by approximately one-third, though this magnitude cannot be interpreted as a causal attribution because NIC may be endogenous. The observation that empagliflozin, which experienced a..."

Journal • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Preliminary Evaluation of SGLT2 Inhibitors in Human Bladder Cancer T24 Cells. (PubMed, Biomedicines) - "In this preliminary study, we assessed the effects of canagliflozin, dapagliflozin, and empagliflozin on metabolic activity, cell cycle distributions, migratory behavior, and SGLT2 expression in the human bladder cancer cell line T24. However, these findings do not establish SGLT2-specific mechanisms and were obtained at concentrations exceeding typical clinical plasma exposure. Further target-validation and mechanistic studies are required."

Journal • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Plasma as Proxy for Tissue Metabolism When Extending Lifespan in Mice. (PubMed, Metabolites) - " We used untargeted metabolomic data from plasma, liver, gastrocnemius muscle, kidney, inguinal fat, and gonadal fat tissues from mice treated with lifespan-extending interventions: caloric restriction, rapamycin, canagliflozin, 17-α estradiol, and acarbose. Overall, plasma can only serve as limited proxy for tissue metabolism. Yet, several potential blood biomarkers were discovered as concordant in plasma and tissues in lifespan-extending interventions."

Journal • Preclinical

Influence of Major Histocompatibility Complex (MHC) Diversity on Immune Modulation, Pathogenesis, and Control of Lumpy Skin Disease Virus. (PubMed, Recent Adv Antiinfect Drug Discov) - "Lumpy Skin Disease continues to pose a major threat to global cattle health and livestock economies. Advances in molecular diagnostics, genomic surveillance, antiviral drug discovery, and BoLA-guided vaccine design provide promising opportunities for improved disease control. Understanding the interaction between LSDV and the bovine MHC system is essential for developing next-generation vaccines, immunotherapeutics, and precision disease-management strategies. Future research should prioritise experimental validation of predicted epitopes, large-scale vaccine trials, and mechanistic studies on host-virus immune interactions to establish effective and sustainable global control programs for LSDV."

IO biomarker • Journal • Dermatology • Dermatopathology • Immune Modulation • Immunology • Infertility • Sexual Disorders

Mg-Based Micromotor Enhanced Targeted Delivery and DESI Mass Spectrometry Imaging of Canagliflozin. (PubMed, Chem Asian J) - "Meanwhile, this Mg-based micromotor has no interference with MS and MSI detection of the drug. Overall, the strategy of combining the active drug delivery of Mg-based micromotors with mass spectrometry detection provides a new method for the detection of low-dose drugs, their localization in tissues, and the evaluation of therapeutic efficacy."

Journal

Canagliflozin Enhances MAPK Inhibition and Delays Resistance in BRAF-Mutant Melanoma (ACS-CLINCON 2026) - "Abstract is embargoed at this time."

Melanoma • Solid Tumor • BRAF

SGLT2 Inhibitors: Dual Effects on Erythropoiesis and Bone Metabolism. (PubMed, J Bone Metab) - "Although canagliflozin has been associated with reduction in hip BMD and possible fracture risk, findings from the drug class remain inconsistent and are often confounded by baseline comorbidities. In conclusion, SGLT2 inhibitors trigger a connected hematologic and mineral changes, but their long-term skeletal impact remains uncertain. Further mechanistic and longitudinal studies are advised to clarify these outcomes."

Journal • Review • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Heart Failure • Hematological Disorders • Metabolic Disorders • Musculoskeletal Diseases • Nephrology • Orthopedics • Renal Disease • Type 2 Diabetes Mellitus • FGF23

AMPK/Autophagy-Dependent Pro-Adipogenic Effect Coupled With Enhanced Lipid Mobilization and Thermogenesis Underlies the Dual Action of Canagliflozin Against Obesity. (PubMed, FASEB J) - "Importantly, SGLT2 expression was undetectable in 3 T3-L1 adipocytes and white adipose tissues. Collectively, CANA exerts anti-obesity effects by reprogramming adipocytes in an SGLT2-independent manner through AMPK/autophagy-dependent differentiation, coupled with enhanced lipolysis and thermogenesis, synergistically driving healthy lipid turnover."

Journal • Diabetes • Dyslipidemia • Genetic Disorders • Metabolic Disorders • Obesity • AMPK

SGLT2 Inhibitors in Cardiovascular-Kidney-Metabolic Syndrome: Drugs Unifying Heart, Kidney, and Metabolism Pharmacotherapy. (PubMed, Am J Cardiovasc Drugs) - "Importantly, SGLT2 inhibitors such as canagliflozin, dapagliflozin, empagliflozin, and sotagliflozin were well tolerated, though caution is advised in volume-depleted patients or those at risk for genitourinary infections. Positive effects, ranging from glycemic control to renoprotective and cardioprotective properties, support SGLT2 inhibitors as first-line therapy in improving clinical outcomes and quality of life in patients affected by this interconnected disease spectrum."

Journal • Review • Cardiovascular • Chronic Kidney Disease • Diabetes • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus • Urology

A randomised controlled study of canagliflozin in improving diabetic kidney disease through a podocyte protection mechanism. (PubMed, Ann Acad Med Singap) - "The reduction in urinary protein appears to be statistically mediated by podocyte protection, rather than being solely dependent on blood glucose control. However, this mediation analysis does not establish causality."

Journal • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus • PODXL

Comparative effectiveness of GLP-1 receptor agonists versus SGLT2 inhibitors in obese patients with valvular heart disease: a target-trial emulation (ESC 2026) - "Background LP-1 receptor agonists (GLP-1RA) and sodium–glucose cotransporter-2 inhibitors (SGLT2i) improve cardiovascular outcomes in high-risk cardiometabolic populations, yet comparative effectiveness data in valvular heart disease (VHD) are sparse.Purpose: To compare 1-year all-cause mortality after initiation of GLP-1RA versus SGLT2i among adults with common non-rheumatic VHD and obesity.MethodsUsing a large federated electronic health record network, we emulated four parallel target trials in adults (≥18 years) with BMI ≥30 kg/m² and a diagnosis of non-rheumatic aortic stenosis, aortic insufficiency, mitral insufficiency, or tricuspid insufficiency recorded within the year before treatment start. Time zero was the first prescription of GLP-1RA (dulaglutide, liraglutide, semaglutide, or tirzepatide) or SGLT2i (canagliflozin, dapagliflozin, or empagliflozin)...In regurgitant lesions, GLP-1RA showed numerically lower mortality in aortic regurgitation (4.2% vs..."

Clinical • HEOR • Cardiovascular • Congestive Heart Failure • Heart Failure

Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fournier Gangrene: A Disproportionality Analysis Using the Japanese Adverse Drug Event Report Database. (PubMed, Am J Ther) - "All 5 SGLT2 inhibitors were associated with FG, with empagliflozin carrying the highest risk. Male patients exhibited elevated susceptibility. Continuous monitoring throughout treatment is essential. Further clinical trials are warranted to clarify causal relationships."

Adverse events • Journal • Genetic Disorders • Obesity

Comparative efficacy of sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: a Bayesian network meta-analysis of randomized controlled trials (ESC 2026) - "Purpose: To rank the comparative efficacy of canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, and ipragliflozin versus placebo on all-cause mortality, cardiovascular mortality, and heart failure hospitalization in patients with HFmrEF/HFpEF. In this Bayesian network meta-analysis of HFmrEF/HFpEF trials, ertugliflozin ranked highest for prevention of heart failure hospitalization and cardiovascular mortality, while ipragliflozin showed the most favorable point estimate for all-cause mortality. However, wide credible intervals and sparse head-to-head data prevent firm conclusions on differential efficacy among SGLT2is. Large, adequately powered head-to-head randomized controlled trials are urgently needed to definitively establish whether meaningful differences exist among individual SGLT2 inhibitors in this population."

Retrospective data • Cardiovascular • Congestive Heart Failure • Heart Failure

Sodium-glucose cotransporter-2 inhibitors and gastrointestinal neoplasm risk in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. (PubMed, Clin Exp Med) - "Subgroup analyses by agents (e.g., canagliflozin, dapagliflozin, empagliflozin), baseline age, body mass index (BMI), HbA1c, treatment duration, and dose were also non-significant (all p > 0.05). However, limited follow-up, low event counts, and non-cancer-specific outcome ascertainment, the findings should be interpreted as reassuring but not definitive evidence of long-term oncologic safety.Systematic review registration: PROSPERO No. CRD42024619019."

Clinical • Journal • Retrospective data • Review • Colorectal Cancer • Diabetes • Gastrointestinal Cancer • Metabolic Disorders • Oncology • Solid Tumor • Type 2 Diabetes Mellitus

Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. (clinicaltrials.gov) - P4 | N=92 | Completed | Sponsor: Fundacin para la Investigacin del Hospital Clnico de Valencia | N=504 ➔ 92 | Active, not recruiting ➔ Completed

Biomarker • Enrollment change • Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

SGLT2 inhibitor outcomes in elderly post-MI patients with mildly reduced ejection fraction: age-stratified real-world evidence (ESC 2026) - "Purpose: To evaluate the comparative effectiveness of SGLT2i (canagliflozin, dapagliflozin, or empagliflozin) initiated within one month post-MI versus no SGLT2i use on cardiovascular and safety outcomes in elderly patients with HFmrEF using a large federated real-world database. In this large real-world analysis, SGLT2i initiation within one month of acute MI in elderly patients with HFmrEF was associated with substantial reductions in mortality, recurrent MI, and progression to HFrEF at one year, with a comparable safety profile. These findings support the early use of SGLT2i in this high-risk elderly population and highlight the need for dedicated randomized trials in post-MI HFmrEF patients aged ≥65 years."

Clinical • HEOR • Real-world • Real-world evidence • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypotension • Myocardial Infarction

SGLT2SOLID: Safety and Efficacy of Canagliflozin in Patients With Locally Advanced or Advanced Solid Cancer (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: West China Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: the CREDENCE trial. (PubMed, Nephrol Dial Transplant) - "Among patients with type 2 diabetes and CKD, the efficacy and safety of canagliflozin appears consistent regardless of polypharmacy status, with larger estimated absolute reductions in hospitalizations and cardiovascular events in those experiencing polypharmacy or hyperpolypharmacy. These findings suggest that polypharmacy alone should not preclude consideration of SGLT2 inhibitor therapy in patients with CKD and type 2 diabetes for whom treatment is otherwise indicated."

Journal • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Blood pressure, electrolyte and fluid balance in horses with insulin dysregulation after short-term treatment with canagliflozin. (PubMed, Vet J) - "Compared to humans, a significant reduction in blood pressure was not observed after short-term canagliflozin treatment. Additionally, there were no significant transient changes in PCV, serum protein or electrolyte concentrations as observed in humans with short-term canagliflozin treatment."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Canagliflozin identifies a distinct phenotype of weight-loss response in type 2 diabetes: a pooled analysis of the CANVAS Program and CREDENCE trials (EASD 2026) - P3, P4 | "Canagliflozin was associated with meaningful weight loss in more than half of participants and identified a distinct phenotype of response characterised by male sex and a more preserved renal profile, beyond baseline adiposity. The predictors of weight loss differed from those seen with placebo, suggesting that treatment-related weight loss with canagliflozin is not simply greater in magnitude, but biologically and clinically distinct."

Retrospective data • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus